|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...6869707172737475767778...110111» |
- |||| HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - May 5, 2014
P1/2, N=143, Completed, Sponsor: Genocea Biosciences, Inc.
Active, not recruiting --> Completed
- Trial completion, Adverse events: Optimal Balloon Catheter Placement During Sonohysterography (clinicaltrials.gov) - May 3, 2014
P4, N=300, Completed, Sponsor: Royan Institute
Active, not recruiting --> Completed Recruiting --> Completed
- Young TIL / National Cancer Institute
Trial primary completion date, Metastases: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers (clinicaltrials.gov) - May 2, 2014
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Trial primary completion date: Apr 2014 --> Feb 2016
- Young TIL / National Cancer Institute
Trial completion date, Metastases: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers (clinicaltrials.gov) - May 2, 2014
P2, N=73, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2014 --> Feb 2016 Trial completion date: Apr 2014 --> Feb 2016
- tanespimycin (BMS-722782) / BMS
Trial initiation date, Combination therapy, Metastases: Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer (clinicaltrials.gov) - May 1, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2014 --> Feb 2016 Initiation date: Jul 2004 --> Oct 2007
- tanespimycin (BMS-722782) / BMS
Trial completion date, Combination therapy, Metastases: Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer (clinicaltrials.gov) - May 1, 2014
P2, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2004 --> Oct 2007 Trial completion date: Feb 2012 --> Mar 2012
- || Trial primary completion date: A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth (clinicaltrials.gov) - May 1, 2014
P=N/A, N=166, Completed, Sponsor: Merck KGaA
Trial completion date: Feb 2012 --> Mar 2012 Trial primary completion date: May 2014 --> Feb 2014
- | Trial completion date: A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth (clinicaltrials.gov) - May 1, 2014
P=N/A, N=166, Completed, Sponsor: Merck KGaA
Trial primary completion date: May 2014 --> Feb 2014 Trial completion date: May 2014 --> Feb 2014
- Trial primary completion date, MRI: MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer (clinicaltrials.gov) - May 1, 2014
P1/2, N=10, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: May 2014 --> Feb 2014 Trial primary completion date: Apr 2014 --> Nov 2014
- Trial completion date, MRI: MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer (clinicaltrials.gov) - May 1, 2014
P1/2, N=10, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Apr 2014 --> Nov 2014 Trial completion date: May 2014 --> Nov 2014
- ||| Trial completion: A Phase IV, Prospective, Observational, Open Label, Single Centre Cohort Trial to be Conducted in Norway During One Year to Assess the Cumulative Pregnancy Rate in a New Series of In-vitro Fertilization (IVF) Treatment Cycles Following Three or More Previous IVF Treatment Cycles Without Live Birth (clinicaltrials.gov) - May 1, 2014
P=N/A, N=166, Completed, Sponsor: Merck KGaA
Trial completion date: May 2014 --> Nov 2014 Active, not recruiting --> Completed
- Trial primary completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Trial primary completion date: May 2013 --> May 2014
- Trial completion date: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: May 2013 --> May 2014 Trial completion date: May 2013 --> May 2014
- Enrollment open: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=150, Recruiting, Sponsor: Regionshospitalet Viborg, Skive
Trial completion date: May 2013 --> May 2014 Active, not recruiting --> Recruiting
- Trial completion: Sex Differences in Early Brain Development; Brain Development in Turner Syndrome (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=295, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Clinical: Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=60, Recruiting, Sponsor: University of Washington
- ISA101 / ISA Pharma
New P1/2 trial, Combination therapy, Metastases: CervISA: Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer (clinicaltrials.gov) - Apr 29, 2014
P1/2, N=48, Recruiting, Sponsor: ISA Pharmaceuticals
- | Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects (clinicaltrials.gov) - Apr 29, 2014
P1, N=40, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Clinical: A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour (clinicaltrials.gov) - Apr 28, 2014
P=N/A, N=1000, Not yet recruiting, Sponsor: University Hospital of North Norway
- |||| Orilissa (elagolix) / AbbVie
Trial primary completion date: A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (clinicaltrials.gov) - Apr 28, 2014
P3, N=788, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Completed Trial primary completion date: Apr 2015 --> Dec 2015
- ||||| Orilissa (elagolix) / AbbVie
Trial initiation date: A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (clinicaltrials.gov) - Apr 28, 2014
P3, N=788, Recruiting, Sponsor: AbbVie
Trial primary completion date: Apr 2015 --> Dec 2015 Initiation date: Oct 2010 --> Sep 2013
- ||| Orilissa (elagolix) / AbbVie
Trial completion date: A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (clinicaltrials.gov) - Apr 28, 2014
P3, N=788, Recruiting, Sponsor: AbbVie
Initiation date: Oct 2010 --> Sep 2013 Trial completion date: Apr 2016 --> Nov 2016
- Nexplanon (etonogestrel implant) / Organon
Enrollment open: Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study (clinicaltrials.gov) - Apr 28, 2014
P2, N=32, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Apr 2016 --> Nov 2016 Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai
Trial completion: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (clinicaltrials.gov) - Apr 28, 2014
P2, N=74, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Enrollment closed: EMR700623_535: Low-dose Gonal-f (clinicaltrials.gov) - Apr 28, 2014
P4, N=110, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cisplatin / Generic mfg.
Trial completion, Metastases: Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer (clinicaltrials.gov) - Apr 28, 2014
P2, N=71, Completed, Sponsor: Korea Cancer Center Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed: Evaluation of the Effectiveness of the POWER Through Choices Program (clinicaltrials.gov) - Apr 27, 2014
P=N/A, N=1080, Active, not recruiting, Sponsor: Mathematica Policy Research, Inc.
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- || Trial primary completion date: Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions (clinicaltrials.gov) - Apr 24, 2014
P2, N=300, Recruiting, Sponsor: Ferring Pharmaceuticals
Enrolling by invitation --> Active, not recruiting Trial primary completion date: Jun 2014 --> Nov 2014
- || Trial completion date: Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions (clinicaltrials.gov) - Apr 24, 2014
P2, N=300, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jun 2014 --> Nov 2014 Trial completion date: Jul 2014 --> Nov 2014
- ||| dovitinib (TKI258) / Allarity Therap, Oncoheroes
Enrollment change, Metastases: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer (clinicaltrials.gov) - Apr 23, 2014
P2, N=53, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jul 2014 --> Nov 2014 N=80 --> 53
- ||| dovitinib (TKI258) / Allarity Therap, Oncoheroes
Enrollment closed, Metastases: A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer (clinicaltrials.gov) - Apr 23, 2014
P2, N=53, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=80 --> 53 Recruiting --> Active, not recruiting
- birinapant (IGM-9427) / IGM Biosciences
Trial completion, Metastases: Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) - Apr 23, 2014
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- New P1 trial: Choline Dehydrogenase and Sperm Function: Effects of Betaine (clinicaltrials.gov) - Apr 22, 2014
P1, N=15, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- Enrollment open: Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=1500, Recruiting, Sponsor: National Development and Research Institutes, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: SUCCESS: Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=600, Recruiting, Sponsor: University of Miami
- Enrollment open: Choline Dehydrogenase and Sperm Function: Effects of Betaine (clinicaltrials.gov) - Apr 21, 2014
P1, N=15, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment open: SUCCESS: Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=600, Recruiting, Sponsor: University of Miami
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Ovidrel (choriogonadotropin alfa) / EMD Serono
Trial initiation date: Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART) (clinicaltrials.gov) - Apr 17, 2014
P3, N=946, Ongoing, Sponsor: Merck KGaA`Merk KGaA
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> Dec 2013
- Clinical: Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=128, Enrolling by invitation, Sponsor: Milton S. Hershey Medical Center
- || Ovidrel (choriogonadotropin alfa) / EMD Serono, Orgalutran (ganirelix acetate) / Organon
New P3 trial, Preclinical: Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response. (clinicaltrials.gov) - Apr 17, 2014
P3, N=232, Recruiting, Sponsor: Instituto de Investigacion Sanitaria La Fe
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression (clinicaltrials.gov) - Apr 17, 2014
P2, N=133, Active, not recruiting, Sponsor: Eisai Inc.
Initiation date: Jan 2014 --> Dec 2013 Trial primary completion date: Dec 2013 --> Jun 2014
- | epacadostat (INCB024360) / Incyte
New P1 trial: Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 17, 2014
P1, N=20, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- Trial completion: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer (clinicaltrials.gov) - Apr 16, 2014
P2, N=15, Completed, Sponsor: University Medical Centre Groningen
Trial primary completion date: Dec 2013 --> Jun 2014 Recruiting --> Completed
- | pemetrexed / Generic mfg.
Trial completion: Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 15, 2014
P2, N=51, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- ||| sofituzumab vedotin (RG 7458) / Roche
Trial completion: Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer (clinicaltrials.gov) - Apr 15, 2014
P1, N=79, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Assessment of Ovarian Reserve Tests in Unexplained Infertile Women (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=80, Recruiting, Sponsor: Karadeniz Technical University
- Xenical (orlistat) / Roche, GSK
Trial completion: OWL-PCOS: Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women (clinicaltrials.gov) - Apr 14, 2014
P2, N=217, Completed, Sponsor: Milton S. Hershey Medical Center
Recruiting --> Completed Active, not recruiting --> Completed
- Metastases: Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer (clinicaltrials.gov) - Apr 13, 2014
P2, N=13, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Recruiting --> Terminated
- Metastases: Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer (clinicaltrials.gov) - Apr 13, 2014
P2, N=13, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Terminated N=43 --> 13
- ||||| HSV vaccine (GEN-003) / Genocea, Shionogi
New P2 trial: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Apr 13, 2014
P2, N=300, Not yet recruiting, Sponsor: Genocea Biosciences, Inc.